Natural killer cells: The journey from puzzles in biology to treatment of cancer

Cancer Letters

Volumn 357, Issue 2, 2015, Pages 454-467

  Bodduluru, Lakshmi Narendra ^a   Kasala, Eshvendar Reddy ^a   Madhana, Rajaram Mohan Rao ^a   Sriram, Chandra Shaker ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Adoptive cell transfer; Cancer; Immunotherapy; NK cells

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; BRYOSTATIN 1; CISPLATIN; CYCLOSPORIN; CYTARABINE; FLUOROURACIL; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 23; IPH 2101; LENALIDOMIDE; LIRILUMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2D; NATURAL KILLER CELL RECEPTOR NKG2DL; NIVOLUMAB; PANOBINOSTAT; POMALIDOMIDE; RECOMBINANT INTERLEUKIN 12; RETINOIC ACID; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; HLA ANTIGEN CLASS 1;

ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL INTERACTION; CELL MEDIATED CYTOTOXICITY; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DNA MODIFICATION; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSURVEILLANCE; KIDNEY CARCINOMA; MACROPHAGE; MELANOMA; NATURAL KILLER CELL; NONHUMAN; PHARMACOLOGICAL BLOCKING; PHENOTYPE; SHORT SURVEY; T LYMPHOCYTE; BIOLOGICAL MODEL; CELL COMMUNICATION; CYTOTOXICITY; IMMUNOLOGY; NEOPLASM; PATHOLOGY;

CELL COMMUNICATION; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; MACROPHAGES; MODELS, IMMUNOLOGICAL; NEOPLASMS; T-LYMPHOCYTES;

EID: 84920813317     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.12.020     Document Type: Review

References (130)

1. GLOBOCAN Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 http://globocan.iarc.fr.
2. Wayteck L., Breckpot K., Demeester J., De Smedt S.C., Raemdonck K. A personalized view on cancer immunotherapy. Cancer Lett 2014, 352:113-125.
3. Ames E., Murphy W.J. Advantages and clinical applications of natural killer cells in cancer immunotherapy. Cancer Immunol. Immunother 2014, 63:21-28.
4. Park J.H., Sauter C., Brentjens R. Cellular therapies in acute lymphoblastic leukemia. Hematol. Oncol. Clin. North Am 2011, 25:1281-1301.
5. Vanneman M., Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 2012, 12:237-251.
6. Cheng M., Chen Y., Xiao W., Sun R., Tian Z. NK cell-based immunotherapy for malignant diseases. Cell. Mol. Immunol 2013, 10:230-252.
7. Phan G.Q., Rosenberg S.A. Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. Cancer Control 2013, 20:289-297.
8. Sun J.C., Beilke J.N., Bezman N.A., Lanier L.L. Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection. J. Exp. Med 2011, 208:357-368.
9. Sun J.C., Beilke J.N., Lanier L.L. Adaptive immune features of natural killer cells. Nature 2009, 457:557-561.
10. Geller M.A., Miller J.S. Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy 2011, 3:1445-1459.
11. Kiessling R., Klein E., Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur. J. Immunol 1975, 5:112-117.
12. Kiessling R., Klein E., Pross H., Wigzell H. "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur. J. Immunol 1975, 5:117-121.
13. Herberman R.B., Nunn M.E., Lavrin D.H. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int. J. Cancer 1975, 16:216-229.
14. Campbell K.S., Hasegawa J. Natural killer cell biology: an update and future directions. J. Allergy Clin. Immunol 2013, 132:536-544.
15. Sutlu T., Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J. Intern. Med 2009, 266:154-181.
16. Inngjerdingen M., Kveberg L., Naper C., Vaage J.T. Natural killer cell subsets in man and rodents. Tissue Antigens 2011, 78:81-88.
17. Kärre K., Ljunggren H.G., Piontek G., Kiessling R. Selective rejection of H2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986, 319:675-678.
18. Brumbaugh K.M., Binstadt B.A., Leibson P.J. Signal transduction during NK cell activation: balancing opposing forces. Curr. Top. Microbiol. Immunol 1998, 230:103-122.
19. MacFarlane I.V.A.W., Campbell K.S. Signal transduction in natural killer cells. Curr. Top. Microbiol. Immunol 2006, 298:23-57.
20. Lanier L.L. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol 2008, 9:495-502.
21. Mentlik James A., Cohen A.D., Campbell K.S. Combination immune therapies to enhance anti-tumor responses by NK cells. Front. Immunol 2013, 4:481.
22. Malhotra A., Shanker A. NK cells: immune cross-talk and therapeutic implications. Immunotherapy 2011, 3:1143-1166.
23. Terszowski G., Passweg J.R., Stern M. Natural killer cell immunity after transplantation. Swiss Med. Wkly 2012, 142:w13700.
24. Bauer S., Groh V., Wu J., Steinle A., Phillips J.H., Lanier L.L., et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999, 285:727-729.
25. Cosman D., Mullberg J., Sutherland C.L., Chin W., Armitage R., Fanslow W., et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001, 14:123-133.
26. Koch J., Steinle A., Watzl C., Mandelboim O. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol 2013, 34:182-191.
27. Joyce M.G., Sun P.D. The structural basis of ligand recognition by natural killer cell receptors. J. Biomed. Biotechnol 2011, 2011:203628. 10.1155/2011/203628.
28. Kim S., Poursine-Laurent J., Truscott S.M., Lybarger L., Song Y.J., Yang L., et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005, 436:709-713.
29. Fernandez N.C., Treiner E., Vance R.E., Jamieson A.M., Lemieux S., Raulet D.H. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 2005, 105:4416-4423.
30. Raulet D.H., Vance R.E. Self-tolerance of natural killer cells. Nat. Res. Immunol 2006, 6:520-531.
31. Chalifour A., Scarpellino L., Back J., Brodin P., Devevre E., Gros F., et al. A Role for cis interaction between the inhibitory Ly49A receptor and MHC Class I for natural killer cell education. Immunity 2009, 30:337-347.
32. Andersson K.E., Williams G.S., Davis D.M., Hoglund P. Quantifying the reduction in accessibility of the inhibitory NK cell receptor Ly49A caused by binding MHC class I proteins in cis. Eur. J. Immunol 2007, 37:516-527.
33. Brodin P., Lakshmikanth T., Johansson S., Karre K., Hoglund P. The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells. Blood 2009, 113:2434-2441.
34. Joncker N.T., Fernandez N.C., Treiner E., Vivier E., Raulet D.H. NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model. J. Immunol 2009, 182:4572-4580.
35. Langers I., Renoux V.M., Thiry M., Delvenne P., Jacobs N. Natural killer cells: role in local tumor growth and metastasis. Biologics 2012, 6:73-82.
36. Angiolillo A.L., Sgadari C., Taub D.D., Liao F., Farber J.M., Maheshwari S., et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med 1995, 182:155-162.
37. Purdy A.K., Campbell K.S. Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol. Ther 2009, 8:2211-2220.
38. Lakshmi Narendra B., Eshvendar Reddy K., Shantikumar S., Ramakrishna S. Immune system: a double-edged sword in cancer. Inflamm. Res 2013, 62:823-834.
39. Bryceson Y.T., March M.E., Ljunggren H.G., Long E.O. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol. Rev 2006, 214:73-91.
40. Ferlazzo G., Morandi B. Cross-talks between natural killer cells and distinct subsets of dendritic cells. Front. Immunol 2014, 10:159.
41. Walzer T., Dalod M., Robbins S.H., Zitvogel L., Vivier E. Natural-killer cells and dendritic cells: "l'union fait la force". Blood 2005, 106:2252-2258.
42. Biron C.A., Nguyen K.B., Pien G.C., Cousens L.P., Salazar-Mather T.P. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol 1999, 17:189-220.
43. Gerosa F., Baldani-Guerra B., Nisii C., Marchesini V., Carra G., Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med 2002, 195:327-333.
44. Morandi B., Mortara L., Chiossone L., Accolla R.S., Mingari M.C., Moretta L., et al. Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response. PLoS ONE 2012, 7:e39170.
45. Langenkamp A., Messi M., Lanzavecchia A., Sallusto F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat. Immunol 2000, 1:311-316.
46. Michel T., Hentges F., Zimmer J. Consequences of the crosstalk between monocytes/macrophages and natural killer cells. Front. Immunol 2013, 4:403.
47. Nedvetzki S., Sowinski S., Eagle R.A., Harris J., Vely F., Pende D., et al. Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses. Blood 2007, 109:3776-3785.
48. Welte S., Kuttruff S., Waldhauer I., Steinle A. Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction. Nat. Immunol 2006, 7:1334-1342.
49. Zhou Z., Zhang C., Zhang J., Tian Z. Macrophages help NK cells to attack tumor cells by stimulatory NKG2D ligand but protect themselves from NK killing by inhibitory ligand Qa-1. PLoS ONE 2012, 7:e36928.
50. Zwirner N.W., Domaica C.I. Cytokine regulation of natural killer cell effector functions. Biofactors 2010, 36:274-288.
51. Rosenstein M., Ettinghausen S.E., Rosenberg S.A. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J. Immunol 1986, 137:1735-1742.
52. Atkins M.B., Lotze M.T., Dutcher J.P., Fisher R.I., Weiss G., Margolin K., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol 1999, 17:2105-2116.
53. Zorn E., Nelson E.A., Mohseni M., Porcheray F., Kim H., Litsa D., et al. IL-2 regulates FOXP3 expression in human CD4+ CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006, 108:1571-1579.
54. Malmberg K.J., Bryceson Y.T., Carlsten M., Andersson S., Bjorklund A., Bjorkstrom N.K., et al. NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy. Cancer Immunol. Immunother 2008, 57:1541-1552.
55. Romee R., Leong J.W., Fehniger T.A. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo) 2014, 2014:205796. 10.1155/2014/205796.
56. DeBlaker-Hohe D.F., Yamauchi A., Yu C.R., Horvath-Arcidiacono J.A., Bloom E.T. IL-12 synergizes with IL-2 to induce lymphokine-activated cytotoxicity and perforin and granzyme gene expression in fresh human NK cells. Cell. Immunol 1995, 165:33-43.
57. Hiraki A., Kiura K., Yamane H., Nogami N., Tabata M., Takigawa N., et al. Interleukin-12 augments cytolytic activity of peripheral blood mononuclear cells against autologous lung cancer cells in combination with IL-2. Lung Cancer 2002, 35:329-333.
58. Rossi A.R., Pericle F., Rashleigh S., Janiec J., Djeu J.Y. Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood 1994, 83:1323-1328.
59. Lauwerys B.R., Renauld J.C., Houssiau F.A. Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18. Cytokine 1999, 11:822-830.
60. Chaix J., Tessmer M.S., Hoebe K., Fuséri N., Ryffel B., Dalod M., et al. Cutting edge: priming of NK cells by IL-18. J. Immunol 2008, 181:1627-1631.
61. Fehniger T.A., Shah M.H., Turner M.J., VanDeusen J.B., Whitman S.P., Cooper M.A., et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J. Immunol 1999, 162:4511-4520.
62. Strengell M., Matikainen S., Sirén J., Lehtonen A., Foster D., Julkunen I., et al. IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J. Immunol 2003, 170:5464-5469.
63. Freudenberg M.A., Merlin T., Kalis C., Chvatchko Y., Stübig H., Galanos C. Cutting edge: a murine, IL-12-independent pathway of IFN-γ induction by Gram-negative bacteria based on STAT4 activation by type I IFN and IL-18 signaling. J. Immunol 2002, 169:1665-1668.
64. Moltó L., Carballido J., Manzano L., Martinez-Martin B., Esquivel F., Chafer J., et al. Immunological changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-alpha-2b and IL-2. J. Immunother 1999, 22:260-267.
65. Pavone L., Andrulli S., Santi R., Majori M., Buzio C. Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer. Cancer Immunol. Immunother 2001, 50:82-86.
66. de Rham C., Ferrari-Lacraz S., Jendly S., Schneiter G., Dayer J.M., Villard J. The pro-inflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors. Arthritis Res. Ther 2007, 9:R125.
67. Cooper M.A., Yokoyama W.M. Memory-like responses of natural killer cells. Immunol. Rev 2010, 235:297-305.
68. Keppel M.P., Yang L., Cooper M.A. Murine NK cell intrinsic cytokine-induced memory-like responses are maintained following homeostatic proliferation. J. Immunol 2013, 190:4754-4762.
69. Krieg S., Ullrich E. Novel immune modulators used in hematology: impact on NK cells. Front. Immunol 2013, 3:388.
70. Romagne F., Andre P., Spee P., Zahn S., Anfossi N., Gauthier L., et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009, 114:2667-2677.
71. Luevano M., Madrigal A., Saudemont A. Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy. Cell. Mol. Immunol 2012, 9:310-320.
72. Soriani A., Zingoni A., Cerboni C., Iannitto M.L., Ricciardi M.R., Di Gialleonardo V., et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 2009, 113:3503-3511.
73. Hayashi T., Hideshima T., Akiyama M., Podar K., Yasui H., Raje N., et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br. J. Haematol 2005, 128:192-203.
74. Davies J.O., Stringaris K., Barrett J.A., Rezvani K. Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease. Cytotherapy 2014, 16:1453-1466. 10.1016/j.jcyt.2014.03.009.
75. Bocian K., Borysowski J., Wierzbicki P., Wyzgal J., Klosowska D., Bialoszewska A., et al. Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+ CD25+ tregs. Nephrol. Dial. Transplant 2010, 25:710-717.
76. Seidel U.J., Schlegel P., Lang P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front. Immunol 2013, 27:76.
77. Raffaghello L., Prigione I., Airoldi I., Camoriano M., Levreri I., Gambini C., et al. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004, 6:558-568.
78. Song H., Kim J., Cosman D., Choi I. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cell. Immunol 2006, 239:22-30.
79. Gasser S., Orsulic S., Brown E.J., Raulet D.H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005, 436:1186-1190.
80. Rohner A., Langenkamp U., Siegler U., Kalberer C.P., Wodnar-Filipowicz A. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leuk. Res 2007, 31:1393-1402.
81. Fionda C., Soriani A., Malgarini G., Iannitto M.L., Santoni A., Cippitelli M. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. J. Immunol 2009, 183:4385-4394.
82. Huang B., Sikorski R., Sampath P., Thorne S.H. Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer. J. Immunother 2011, 34:289-296.
83. Fionda C., Malgarini G., Soriani A., Zingoni A., Cecere F., Iannitto M.L., et al. Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3. J. Immunol 2013, 190:6662-6672.
84. Zhou Q., Gil-Krzewska A., Peruzzi G., Borrego F. Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy. Clin. Exp. Immunol 2013, 173:131-139.
85. Levy E.M., Roberti M.P., Mordoh J. Natural killer cells in human cancer: from biological functions to clinical applications. J. Biomed. Biotechnol 2011, 676198:2011.
86. Ghiringhelli F., Menard C., Terme M., Flament C., Taieb J., Chaput N., et al. CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med 2005, 202:1075-1085.
87. Miller J.S., Tessmer-Tuck J., Pierson B.A., Weisdorf D., McGlave P., Blazar B.R., et al. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. Biology of blood and marrow transplantation. Biol. Blood Marrow Transplant 1997, 3:34-44.
88. Burns L.J., Weisdorf D.J., DeFor T.E., Vesole D.H., Repka T.L., Blazar B.R., et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant 2003, 32:177-186.
89. Raulet D.H., Held W. Natural killer cell receptors: the offs and ons of NK cell recognition. Cell 1995, 82:697-700.
90. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
91. Cheng M., Zhang J., Jiang W., Chen Y., Tian Z. Natural killer cell lines in tumor immunotherapy. Front. Med 2012, 6:56-66.
92. Tonn T., Becker S., Esser R., Schwabe D., Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J. Hematother. Stem Cell Res 2001, 10:535-544.
93. Arai S., Meagher R., Swearingen M., Myint H., Rich E., Martinson J., et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 2008, 10:625-632.
94. Tonn T., Schwabe D., Klingemann H.G., Becker S., Esser R., Koehl U., et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 2013, 15:1563-1570.
95. Parkhurst M.R., Riley J.P., Dudley M.E., Rosenberg S.A. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin. Cancer Res 2011, 17:6287-6297.
96. Krause S.W., Gastpar R., Andreesen R., Gross C., Ullrich H., Thonigs G., et al. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells A clinical phase I trial. Clin. Cancer Res 2004, 10:3699-3707.
97. Rubnitz J.E., Inaba H., Ribeiro R.C., Pounds S., Rooney B., Bell T., et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J. Clin. Oncol 2010, 28:955-959.
98. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun G.H., Fautsch S.K., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
99. Curti A., Ruggeri L., D'Addio A., Bontadini A., Dan E., Motta M.R., et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 2011, 118:3273-3279.
100. Stern M., Passweg J.R., Meyer-Monard S., Esser R., Tonn T., Soerensen J., et al. Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. Bone Marrow Transplant 2013, 48:433-438.
101. Brehm C., Huenecke S., Quaiser A., Esser R., Bremm M., Kloess S., et al. IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study. PLoS ONE 2011, 6:e27351.
102. Yoon S.R., Lee Y.S., Yang S.H., Ahn K.H., Lee J.H., Lee J.H., et al. Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant 2010, 45:1038-1046.
103. Passweg J.R., Tichelli A., Meyer-Monard S., Heim D., Stern M., Kühne T., et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004, 18:1835-1838.
104. Shi J., Tricot G., Szmania S., Rosen N., Garg T.K., Malaviarachchi P.A., et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br. J. Haematol 2008, 143:641-653.
105. Bachanova V., Burns L.J., McKenna D.H., Curtsinger J., Panoskaltsis-Mortari A., Lindgren B.R., et al. Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol. Immunother 2010, 59:1739-1744.
106. Geller M.A., Cooley S., Judson P.L., Ghebre R., Carson L.F., Argenta P.A., et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011, 13:98-107.
107. Barkholt L., Alici E., Conrad R., Sutlu T., Gilljam M., Stellan B., et al. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy 2009, 1:753-764.
108. Iliopoulou E.G., Kountourakis P., Karamouzis M.V., Doufexis D., Ardavanis A., Baxevanis C.N., et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol. Immunother 2010, 59:1781-1789.
109. Nagashima S., Mailliard R., Kashii Y., Reichert T.E., Herberman R.B., Robbins P., et al. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood 1998, 91:3850-3861.
110. Tam Y.K., Maki G., Miyagawa B., Hennemann B., Tonn T., Klingemann H.G. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum. Gene Ther 1999, 10:1359-1373.
111. Jiang W., Zhang J., Tian Z. Functional characterization of interleukin-15 gene transduction into the human natural killer cell line NKL. Cytotherapy 2008, 10:265-274.
112. Zhang J., Sun R., Wei H., Tian Z. Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy. Haematologica 2004, 89:338-347.
113. Uherek C., Tonn T., Uherek B., Becker S., Schnierle B., Klingemann H.G., et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 2002, 100:1265-1273.
114. Demirtzoglou F.J., Papadopoulos S., Zografos G. Cytolytic and cytotoxic activity of a human natural killer cell line genetically modified to specifically recognize HER-2/neu overexpressing tumor cells. Immunopharmacol. Immunotoxicol 2006, 28:571-590.
115. Meier R., Piert M., Piontek G., Rudelius M., Oostendorp R.A., Senekowitsch-Schmidtke R., et al. Tracking of [18F] FDG-labeled natural killer cells to HER2/neu-positive tumors. Nucl. Med. Biol 2008, 35:579-588.
116. Schirrmann T., Pecher G. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo. Cancer Gene Ther 2002, 9:390-398.
117. Schirrmann T., Pecher G. Specific targeting of CD33+ leukemia cells by a natural killer cell line modified with a chimeric receptor. Leuk. Res 2005, 29:301-306.
118. Muller T., Uherek C., Maki G., Chow K.U., Schimpf A., Klingemann H.G., et al. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol. Immunother 2008, 57:411-423.
119. Imai C., Iwamoto S., Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005, 106:376-383.
120. Kruschinski A., Moosmann A., Poschke I., Norell H., Chmielewski M., Seliger B., et al. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:17481-17486.
121. Pegram H.J., Jackson J.T., Smyth M.J., Kershaw M.H., Darcy P.K. Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo. J. Immunol 2008, 181:3449-3455.
122. Wennerberg E., Kremer V., Childs R., Lundqvist A. CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo. Cancer Immunol. Immunother 2014, 10.1007/s00262-014-1629-5.
123. Maki G., Krystal G., Dougherty G., Takei F., Klingemann H.G. Induction of sensitivity to NK-mediated cytotoxicity by TNF-alpha treatment: possible role of ICAM-3 and CD44. Leukemia 1998, 12:1565-1572.
124. Costello R.T., Sivori S., Marcenaro E., Lafage-Pochitaloff M., Mozziconacci M.J., Reviron D., et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002, 99:3661-3667.
125. Chretien A.S., Le Roy A., Vey N., Prebet T., Blaise D., Fauriat C., et al. Cancer-induced alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity. Front. Immunol 2014, 5:122.
126. Waldhauer I., Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008, 27:5932-5943.
127. Otsuji M., Kimura Y., Aoe T., Okamoto Y., Saito T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:13119-13124.
128. Sabry M., Lowdell M.W. Tumor-primed natural killer cells: waiting for the green light. Front. Immunol 2013, 4:408.
129. Kiessling R., Wasserman K., Horiguchi S., Kono K., Sjoberg J., Pisa P., et al. Tumor-induced immune dysfunction. Cancer Immunol. Immunother 1999, 48:353-362.
130. Morse M.A., Mosca P.J., Clay T.M., Lyerly H.K. Dendritic cell maturation in active immunotherapy strategies. Expert Opin. Biol. Ther 2002, 2:35-43.